The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease

被引：1
作者：
Kawada, Tomoyuki [1 ]
机构：
[1] Nippon Med Sch, Dept Hyg & Publ Hlth, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138602, Japan
来源：
CLINICAL AND EXPERIMENTAL NEPHROLOGY | 2016年 / 20卷 / 01期
关键词：
Estimated glomerular filtration rate; Autosomal dominant polycystic kidney disease; Tolvaptan; Validity;
D O I：
10.1007/s10157-015-1134-y
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：147 / 148
页数：2
相关论文
共 50 条
  • [41] Effectiveness of Tolvaptan in the Treatment for Patients with Autosomal Dominant Polycystic Kidney Disease: A Meta-analysis
    Xie, Xuan
    Cai, Qian
    Guo, Xiao-Yuan
    Bai, Dong-Hai
    Sheng, Hai-Zhong
    Wang, Bao-Kui
    Yan, Kai
    Lu, An-Ming
    Wang, Xin-Ran
    COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2020, 23 (01) : 6 - 16
  • [42] Long-Term Effects of High-Dose Tolvaptan for Autosomal Dominant Polycystic Kidney Disease Patients
    Nakatani, Shinya
    Ishimura, Eiji
    Machiba, Yuri
    Fujimoto, Kenta
    Uedono, Hideki
    Tsuda, Akihiro
    Mori, Katsuhito
    Emoto, Masanori
    Inaba, Masaaki
    CASE REPORTS IN NEPHROLOGY AND DIALYSIS, 2020, 10 (01): : 9 - 17
  • [43] Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial
    Casteleijn, Niek F.
    Blais, Jaime D.
    Chapman, Arlene B.
    Czerwiec, Frank S.
    Devuyst, Olivier
    Higashihara, Eiji
    Leliveld, Anna M.
    Ouyang, John
    Perrone, Ronald D.
    Torres, Vicente E.
    Gansevoort, Ron T.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2017, 69 (02) : 210 - 219
  • [44] Estimating risk of rapid disease progression in pediatric patients with autosomal dominant polycystic kidney disease: a randomized trial of tolvaptan
    Mekahli, Djalila
    Guay-Woodford, Lisa M.
    Cadnapaphornchai, Melissa A.
    Goldstein, Stuart L.
    Dandurand, Ann
    Jiang, Huan
    Jadhav, Pravin
    Debuque, Laurie
    PEDIATRIC NEPHROLOGY, 2024, 39 (05) : 1481 - 1490
  • [45] Estimating risk of rapid disease progression in pediatric patients with autosomal dominant polycystic kidney disease: a randomized trial of tolvaptan
    Djalila Mekahli
    Lisa M. Guay-Woodford
    Melissa A. Cadnapaphornchai
    Stuart L. Goldstein
    Ann Dandurand
    Huan Jiang
    Pravin Jadhav
    Laurie Debuque
    Pediatric Nephrology, 2024, 39 : 1481 - 1490
  • [46] Magnetic resonance imaging is effective for evaluating the therapeutic effect of tolvaptan on total kidney volume in patients with autosomal dominant polycystic kidney disease
    Hirashio S.
    Doi S.
    Masaki T.
    Renal Replacement Therapy, 4 (1)
  • [47] Nutritional Status is Associated With Preserved Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease
    Lee, Jinwoo
    Ryu, Hyunjin
    Kim, Yong-Chul
    Park, Hayne Cho
    Ahn, Curie
    Lee, Kyu-Beck
    Kim, Yeong Hoon
    Kim, Yaerim
    Han, Seungyeop
    Bae, Eun Hui
    Oh, Kook-Hwan
    Oh, Yun Kyu
    JOURNAL OF RENAL NUTRITION, 2023, 33 (04) : 529 - 537
  • [48] Autosomal Dominant Polycystic Kidney Disease
    Suarez, Maria Lourdes Gonzalez
    Titan, Silvia
    Dahl, Neera K.
    ADVANCES IN KIDNEY DISEASE AND HEALTH, 2024, 31 (06): : 496 - 503
  • [49] Assessing the Risk of Progression to Kidney Failure in Patients With Autosomal Dominant Polycystic Kidney Disease
    Lanktree, Matthew B.
    Kline, Timothy
    Pei, York
    ADVANCES IN KIDNEY DISEASE AND HEALTH, 2023, 30 (05): : 407 - 416
  • [50] Clinical characteristics and outcomes of kidney transplantation in autosomal dominant polycystic kidney disease patients
    Lee, Jin Hyeog
    Myung, Jiyeon
    Gang, Sujin
    Ryu, Hyun Jin
    Yi, Nam Joon
    Yang, Jaeseok
    JOURNAL OF NEPHROLOGY, 2024,
12345